Which is the original drug R&D manufacturer of Quizartinib?

Quizartinib was originally developed by Ambit Biosciences, a California-based biopharmaceutical company dedicated to developing small molecule drugs targeting kinases. The company focused on the field of oncology in its early days, especially in the targeted treatment of FLT3-mutated acute myeloid leukemia (AML) and accumulated a solid research foundation. QuizatinibAs its core product, it has become one of the first oral drugs in the world to specifically target FLT3-ITD mutations, and has shown good drug prospects in multiple clinical studies.

In 2014, Japanese pharmaceutical giant Daiichi Sankyo acquired Ambit Biosciences and incorporated the research and development and registration applications of Quizartinib into its global oncology product line. As one of Japan's largest multinational pharmaceutical companies, Daiichi Sankyo has further enhanced its competitiveness in the targeted tumor treatment market through this acquisition.

After successfully completing multiple clinical trials, Daiichi Sankyo received approval from the U.S. FDA in 2023 to use quizartinib (trade name: Vanflyta) to treat newly diagnosed adult patients with FLT3-ITD-positive acute myeloid leukemia. This approval marks the drug becoming the world's first oral targeted drug for the treatment of newly diagnosed FLT3-ITD-positive AML.

Therefore, from the early stage of research and development in the United StatesAmbit Biosciences, to its subsequent acquisition by Japan's Daiichi Sankyo and its promotion to global listing, Quizartinib is a typical successful case of cross-border cooperative research and development. Its original research background not only has the ability to develop innovative drugs, but also benefits from the support of international drug registration management experience, making it one of the important choices for targeted treatment of leukemia.

Reference materials:https://go.drugbank.com/drugs/DB12874